Stock
Stock

Compugen

1.44

Delay
0
Open
1.48
Market Cap
134.66M+
High
1.49
Low
1.44
Close
1.44
Volume
281.69K+
P/E Ratio
-10.31
Div/Yield
0.00%
Track The Stock Movement

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Trade GPT

logo

Compañía

Social

Descargar

google playapp store

© 2025 Rockalpha Limited. Todos los Derechos Reservados.

Rockalpha Limited está inscrita en el Registro de Proveedores de Servicios Financieros de Nueva Zelanda (FSP: 1001454). El registro de Proveedores de Servicios Financieros de Rockalpha Limited puede verificarse en el Registro de Proveedores de Servicios Financieros. Rockalpha Limited es miembro del Insurance & Financial Services Ombudsman Scheme, un proveedor independiente de servicios de resolución de disputas. Rockalpha Limited no está autorizada por ningún organismo regulador neozelandés para prestar servicios monetarios o inmobiliarios a clientes, y la inscripción de Rockalpha Limited en el registro neozelandés de proveedores de servicios financieros o su pertenencia al Insurance & Financial Services Ombudsman Scheme no significa que Rockalpha Limited esté sujeta a la regulación o supervisión activa de un organismo regulador neozelandés.Rockalpha Limited está inscrita en el Registro de Proveedores de Servicios Financieros de Nueva Zelanda (FSP: 1001454). El registro de Proveedores de Servicios Financieros de Rockalpha Limited puede verificarse en el Registro de Proveedores de Servicios Financieros. Rockalpha Limited es miembro del Insurance & Financial Services Ombudsman Scheme, un proveedor independiente de servicios de resolución de conflictos.

Rockalpha Limited, operates from its Singapore headquarters at CapitaSky 808, 79 Robinson Road, Singapore 068897, with a regional office at Level 6, Core C, Cyberport 3, 100 Cyberport Road, Hong Kong.